Regeneron Pharmaceuticals Stock Retreats After Asthma Antibody Data

Analyst sentiment has been mostly pessimistic

Managing Editor
Jun 21, 2019 at 9:45 AM
facebook X logo linkedin

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is moving lower this morning, last seen down 0.9% at $317.63, even after the drugmaker revealed positive topline results from a Phase 2 study of its IL-33 antibody in asthma, being developed with Sanofi (SNY). Specifically, the antibody met its main goal of improving of asthma control and its secondary endpoint of improving lung function.

Cantor Fitzgerald was quick to weigh in, reiterating its "neutral" rating and $405 price target, saying there are some "important questions that need to be answered about this target beyond the press release." More broadly, 13 firms following Regeneron stock sport tepid "hold" ratings, compared to six carrying a "strong buy" recommendations. Meanwhile, REGN's average 12-month price target of $387.85 is a 21% premium to current levels.

In the options pits, traders have been leaning bearish. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows REGN with a 10-day put/call volume ratio of 1.37, which ranks in the 97th annual percentile. In simpler terms, puts have been purchased over calls at a faster-than-usual clip.

Following a long-term downtrend on the charts, Regeneron stock bottomed at $295.27 in early June. The shares have climbed off this level, and peaked above their 50-day moving average yesterday for the first time since early April. However, the stock has not closed above this trendline since mid-March, and remains 15% lower year-to-date.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI